Literature DB >> 17576297

Less-oxidative hemodialysis solution rendered by cathode-side application of electrolyzed water.

Masaaki Nakayama1, Shigeru Kabayama, Hiroyuki Terawaki, Keisuke Nakayama, Kiyoshi Kato, Toshinobu Sato, Sadayoshi Ito.   

Abstract

Electrolyzed water (EW) generated on the cathode side reportedly displays anti-oxidative properties, and application of EW to hemodialysis (HD) systems supposedly suppresses oxidative markers in patients on HD. However, most of the chemical properties and biological effects of such solutions remain unclear. This study aimed to examine those issues to clarify the scientific background for the clinical use of EW solution. Reverse osmosis water comprising EW from the cathode side (e-RO) was prepared and used to process a test HD solution (e-HD). Chemical and biological properties of these solutions were compared with controls. Redox properties were examined by chemiluminescence (CL) of the luminol-H(2)O(2) system. Biological effects of e-RO on human polymorphonuclear leukocytes (PMNs) were tested with respect to the cellular protection against methylglyoxal, and with respect to the preservation of cellular function as to radical generation. Control HD solution presented the highest CL, followed by e-HD, control RO, suggesting a lower oxidative capacity for EW-based solutions. Increased levels of dissolved hydrogen were characteristic of e-RO and e-HD. Application of e-RO tended to be associated with less injury of PMNs by methylglyoxal, and with significantly higher levels of radical generation compared with the control. Compared with control HD, e-RO-based HD solution displays less-oxidative capacity in chemical terms, and may at least partly facilitate preservation of PMN viability. These results appear to offer a scientific basis for supporting the clinical challenge of applying this technology to HD treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576297     DOI: 10.1111/j.1542-4758.2007.00187.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  5 in total

1.  Successful treatment of encapsulating peritoneal sclerosis by hemodialysis and peritoneal lavage using dialysate containing dissolved hydrogen.

Authors:  Hiroyuki Terawaki; Hirofumi Nakano; Wan-Jun Zhu; Masaaki Nakayama
Journal:  Perit Dial Int       Date:  2015 Jan-Feb       Impact factor: 1.756

2.  Dialysate with high dissolved hydrogen facilitates dissociation of indoxyl sulfate from albumin.

Authors:  Yoshihiro Tange; Shingo Takesawa; Shigenori Yoshitake
Journal:  Nephrourol Mon       Date:  2015-02-25

3.  Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study.

Authors:  Masaaki Nakayama; Noritomo Itami; Hodaka Suzuki; Hiromi Hamada; Ryo Yamamoto; Kazumasa Tsunoda; Naoyuki Osaka; Hirofumi Nakano; Yukio Maruyama; Shigeru Kabayama; Ryoichi Nakazawa; Mariko Miyazaki; Sadayoshi Ito
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

4.  Dissolved molecular hydrogen (H2) in Peritoneal Dialysis (PD) solutions preserves mesothelial cells and peritoneal membrane integrity.

Authors:  Masaaki Nakayama; Wan-Jun Zhu; Kimio Watanabe; Ayano Gibo; Ali M Sherif; Shigeru Kabayama; Sadayoshi Ito
Journal:  BMC Nephrol       Date:  2017-10-31       Impact factor: 2.388

5.  Possible clinical effects of molecular hydrogen (H2) delivery during hemodialysis in chronic dialysis patients: Interim analysis in a 12 month observation.

Authors:  Masaaki Nakayama; Noritomo Itami; Hodaka Suzuki; Hiromi Hamada; Naoyuki Osaka; Ryo Yamamoto; Kazumasa Tsunoda; Hirofumi Nakano; Kimio Watanabe; Wan-Jun Zhu; Yukio Maruyama; Hiroyuki Terawaki; Shigeru Kabayama; Ryoichi Nakazawa; Mariko Miyazaki; Sadayoshi Ito
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.